BioCryst Pharmaceuticals reported strong Q2 2026 financial results with total net revenue of $218.3 million, driven by ORLADEYO sales of $158.2 million. The company began shipping ORLADEYO oral pellets to pediatric patients, marking a key milestone in hereditary angioedema treatment. BioCryst completed enrollment in a pivotal trial for its investigational drug navenibart and raised its total revenue guidance for 2026 to $690-$715 million. The company is focusing on external innovation and cost discipline to sustain growth and profitability.
Ocular Therapeutix received a Buy (speculative) rating with a 12-month price target of $7.90 following strong Phase 3 SOL-1 trial results. The positive data supports a clear regulatory path, with a New Drug Application (NDA) filing expected in Q4 and...
A 25-times-leveraged Ether (ETH) long position was fully liquidated during a brief crypto market drop, resulting in a net loss exceeding $180,000. The trader later reopened a smaller long position holding 115 ETH, valued at about $269,000, with a liq...
Avalanche (AVAX) was trading at $8.85 as of early October 25, slightly down by 1.02% over the past 24 hours. Crypto analyst Giannis Andreou identified a support range between $8.50 and $8.90, which AVAX is currently within. If this support holds, And...
On October 25, Binance's Ether (ETH) perpetual market displayed a sell surplus of approximately $2.68 million, with sell orders totaling $59.45 million against buy orders of $56.77 million. At the time, Ether was priced at $2,343.23. The spot order b...
MemeCore (M) price fell about 10% on October 25, 2026, due to a structural unwind in leveraged positions and low genuine trading volume, rather than any specific news or token event. The token's price reversal followed a rally with declining spot vol...
